What Ofuxal Treats: Main Uses and Benefits

Ofuxal is an alpha-1 blocker medication primarily used to manage symptoms associated with certain urological conditions. Its active ingredient, alfuzosin, acts on specific receptors to help improve urinary flow and comfort.

Primary Indications

The medication is most commonly used for the following purposes:

• Benign Prostatic Hyperplasia (BPH): Ofuxal is used to treat the symptoms of an enlarged prostate, a non-cancerous condition common in aging men. By relaxing the smooth muscles in the prostate and the neck of the bladder, it helps alleviate urinary difficulties.
• Acute Urinary Retention (AUR): In some cases, it is used as an adjunctive therapy for patients experiencing a sudden inability to urinate. It may be administered alongside catheterization to increase the likelihood of successful voiding after the catheter is removed.

Key Benefits and Effects

By targeting the muscle tissues involved in urination, the medication provides several clinical benefits:

• Improved Urinary Flow: By reducing the resistance at the bladder outlet, it helps the urine flow more freely and strongly.
• Reduction of Lower Urinary Tract Symptoms (LUTS): It addresses common issues such as the frequent urge to urinate (especially at night), a weak or interrupted stream, and the sensation that the bladder is not completely empty.
• Rapid Symptom Relief: Unlike some other prostate treatments that may take months to show results, the relaxing effect on smooth muscle typically begins to improve urinary symptoms shortly after starting the treatment.
• Selective Action: The medication is designed to target receptors in the urinary tract more specifically, which helps maintain efficacy while minimizing effects on systemic blood pressure.

Eligibility Profile: Official Regulatory Rules

Ofuxal (Alfuzosin hydrochloride) is officially indicated for use only in adult men to manage symptoms related to Benign Prostatic Hyperplasia (BPH). Its eligibility profile is strictly defined by regulatory authorities based on specific patient demographics, organ function, and concurrent medications.

---

Absolute Contraindications

Use of this medicine is prohibited in specific patient groups, as defined in the official labeling:

• Severe Hepatic Impairment: The medicine is contraindicated in patients with moderate or severe liver impairment (Childs-Pugh B and C).
• Hypersensitivity: Patients with known hypersensitivity to Alfuzosin or any component of the tablet.
• Concurrent Medication Use: Contraindicated in patients concurrently taking other alpha-1 blockers or potent CYP3A4 inhibitors (such as certain antivirals or antifungals).
• Orthostatic Hypotension: A history of orthostatic hypotension may be listed as a contraindication in some regulatory documents.

---

Restricted or Non-Recommended Use

• Severe Renal Impairment: Use is not recommended in patients with severe kidney problems (creatinine clearance < 30 mL/min), as safety data are limited.
• Cardiovascular Conditions: Caution is required for patients with a history of QT prolongation or those with coronary insufficiency. If angina worsens, use must be discontinued.
• Age and Gender: The medicine is not indicated for use in women or the pediatric population (under 18 years) as the BPH indication is male-specific and efficacy in children is not established.

Interactions with other medicines and products

The interaction profile for Alfuzosin hydrochloride is officially documented through specific pharmacokinetic and pharmacodynamic restrictions, as defined by regulatory authorities.

Formal Restrictions and Contraindications

Co-administration is formally contraindicated with certain substances due to the risk of severe interaction:

• Potent CYP3A4 Inhibitors: Medicines such as Ketoconazole and Ritonavir are prohibited. These substances block the primary enzyme responsible for Alfuzosin metabolism, which is officially documented to significantly increase Alfuzosin exposure and blood levels.
• Other Alpha-1 Adrenergic Antagonists: The use of other medicines belonging to the alpha-blocker class is prohibited due to the potential for severe additive effects, specifically a high risk of symptomatic hypotension.

Clinically Significant Interactions

The potential for pharmacodynamic interactions extends to other medications that affect blood pressure. The risk of hypotension is officially documented to increase when Alfuzosin is co-administered with antihypertensive drugs, nitrates, or Phosphodiesterase-5 (PDE5) inhibitors (e.g., Sildenafil). Moderate CYP3A4 inhibitors, such as Diltiazem, also increase Alfuzosin plasma concentrations.

Administration and Clearance Constraints

A critical constraint is the mandatory requirement to take the extended-release tablet with food. Administration in a fasted state is officially documented to reduce absorption by 50%. Furthermore, the medicine is contraindicated in patients with moderate or severe hepatic impairment because their reduced clearance leads to increased Alfuzosin blood levels.

Targeting Alpha-1 Adrenergic Receptors to Block Sympathetic Signals

The core action of Alfuzosin is a competitive blockade of the post-synaptic alpha1-adrenoceptors, which are concentrated on smooth muscle tissue in the lower urinary tract . By occupying the receptor site, the drug prevents the endogenous neurotransmitter norepinephrine from initiating its signal, thus suppressing the sympathetic input that initiates muscle contraction.

---

Molecular Cascade and Smooth Muscle Relaxation

Blocking the alpha1-receptor interrupts the internal Gq protein signaling cascade, which normally triggers the release of intracellular calcium ions ( Ca^2+). The resulting suppression of Ca^2+ release leads directly to the relaxation of the smooth muscle tissue in the prostate and bladder neck.

---

Modulation of Dynamic Urethral Resistance

The resulting smooth muscle relaxation is characterized by functional uroselectivity and produces a key physiological change: a reduction of pressure and resistance at the bladder outlet. The mechanism's influence is restricted to the dynamic (muscle tone) component, as opposed to fixed physical volume.

How Ofuxal is Used: Administration Guidelines

Ofuxal is formulated as a 10 mg extended-release tablet and is taken orally. The administration follows specific protocols to ensure consistent absorption of the active ingredient, Alfuzosin hydrochloride.

---

Dosing and Administration

Instruction Entity	Administration Details
Route of Administration	The medication is taken orally (swallowed by mouth).
Standard Dosing	The recommended dosage is one 10 mg extended-release tablet per day.
Timing in Relation to Meals	Must be taken immediately after the same meal each day. The absorption of Alfuzosin is 50% lower if taken in a fasting state.
Preparation Requirements	The tablet must be swallowed whole with a sufficient amount of liquid.
Missed Dose Rules	If a dose is missed, the patient should skip the missed dose and resume the schedule with the next dose. Do not take two tablets at the same time to compensate.

---

Procedural and Population Constraints

Special Procedural Conditions

The extended-release tablet must not be chewed, crushed, or split. Breaking the tablet compromises the controlled-release mechanism, which may lead to inappropriate absorption of the entire dose.

Population-Specific Rules

• Pediatric Use: The medication is not indicated for use in the pediatric population (patients under 18 years of age).
• Older Adults: No routine dose adjustment is required for geriatric patients (aged 65 years and over).
• Hepatic Impairment: The 10 mg extended-release tablet is contraindicated for use in patients with moderate or severe liver impairment.

This regimen is structured for long-term daily use to provide continuous management of symptoms, and adherence to the fixed, once-daily dose taken with food is central to the prescribing protocol.

Research Evidence / Overview of Studies for Ofuxal

Evidence for Use in Lower Urinary Tract Symptoms (LUTS) due to BPH

Research exploring Alfuzosin in studies for symptoms of an enlarged prostate has been conducted using several different study types. The core evidence stems from multiple randomized, controlled trials (RCTs). In these trials, adult males with moderate to severe LUTS due to Benign Prostatic Hyperplasia (BPH) were given either the study medicine or an inactive substitute called a placebo for a short duration, usually around three months.

In these studies, researchers monitored changes in subjective measures, such as the International Prostate Symptom Score (IPSS). The research also monitored objective measures, such as Peak Urinary Flow Rate (Qmax) and Post-Void Residual (PVR) urine volume. Short-term findings described patterns where patients receiving the medicine had different measurements in these symptom and flow scores compared to patterns observed in the placebo groups.

Evidence in Acute Urinary Retention (AUR) Settings

Research explored Alfuzosin in a specific, acute setting: the temporary inability to pass urine, known as Acute Urinary Retention (AUR), when it is related to BPH. This research involved conducting randomized trials on adult males immediately after they experienced their first episode of AUR and required a catheter. The trials were designed to examine outcomes describing episodic or acute symptom patterns. The main focus was monitoring the proportion of patients who achieved successful catheter-free voiding after the catheter was removed, compared to those receiving a placebo.

Long-Term Studies and Durability of Follow-up

To examine the long-term patterns related to symptoms and flow measures, researchers conducted open-label studies, often as extensions of the original short-term trials, using data from extended-duration observational studies that followed patients for periods extending up to three years or more. Some research also explored long-term BPH progression endpoints, such as the need for BPH-related surgery or the recurrence of AUR.

What is Still Uncertain About the Research

The highest quality comparative evidence (double-blind, placebo-controlled data) is primarily limited to short-term observation periods (around 3 months). Long-term effects are not fully established under those strict trial conditions. Comparative evidence is lacking for direct, head-to-head trials against all alternative alpha-blocker formulations currently available. The research does not predict whether an individual will respond similarly, as findings describe group patterns, not personal outcomes.

Common questions about Ofuxal (FAQ)

Q: How quickly does Ofuxal typically start to show an effect according to studies?

A: Clinical studies observed patterns of symptomatic relief in patients. Official study information indicates that statistically significant improvement in symptoms and urinary flow rates were observed starting at the first monthly follow-up visit (Day 28). This timeframe reflects the pattern observed in the patient groups studied.

Q: I'm worried about the risk of [common side effect]. What does the official documentation say?

A: Official documentation categorizes common adverse reactions based on their frequency in clinical trials. For example, common reactions like dizziness, headache, and fatigue occurred in a specific, small percentage of patients (e.g., 2% to 5.7%). This categorization provides a factual, statistical description of risk derived from official regulatory data.

Q: Do the side effects from Ofuxal usually lessen or go away over time?

A: Some effects, such as drowsiness and dizziness, may be more prominent immediately after the first dose is taken. Official reports indicate that these effects may lessen or decrease in intensity as the body becomes accustomed to the medication over time.

Q: What are the signs of a potential allergic reaction to Ofuxal?

A: The official prescribing information lists hypersensitivity as a potential concern. Symptoms reported for an allergic reaction can include swelling of the face, lips, tongue, or throat, as well as skin rash, hives, or itching. Regulatory information highlights these symptoms as serious and requiring immediate review by a healthcare professional.

Q: Where can I find summaries of the latest research evidence for Ofuxal?

A: Summaries of the latest research, including detailed efficacy and safety data from clinical trials, are contained within the official regulatory prescribing information document. This document, published by governing health bodies, includes a dedicated 'Clinical Studies' section for review.

Q: What are the rules regarding stopping Ofuxal treatment? (Informational description, not advice)

A: According to the official warnings and precautions, the medication should be discontinued if a patient experiences the appearance or worsening of symptoms of angina pectoris (chest pain). This specific instruction is based on safety data and risk mitigation protocols.

Q: How is Ofuxal different from other medicines used for a similar purpose?

A: Regulatory-based scientific reviews describe Alfuzosin as an alpha-blocker that exhibits a selective concentration in the prostate area. This selective functional profile has been associated with specific reported rates of sexual adverse events, as noted in clinical reviews.

Q: Does Ofuxal cause weight gain, weight loss, or changes in appetite?

A: Changes in body weight are not listed as a common or specific side effect in the official regulatory profile. However, post-marketing surveillance reports have included loss of appetite as an adverse event of unknown frequency.

Q: Are there any known food or drink restrictions while taking Ofuxal?

A: Official information states that grapefruit or grapefruit juice should be avoided, as it may increase drug concentration in the body. Alcohol can also increase the risk of side effects like dizziness and fainting.

Q: Can Ofuxal affect my mood, concentration, or sleep patterns?

A: Fatigue and dizziness are common reactions that can affect general alertness and concentration. While confusion is listed as a rare side effect in regulatory documents, specific effects on mood or sleep patterns are not directly addressed in the common side effect listings.

Q: Does Ofuxal interact with common over-the-counter pain relievers like ibuprofen?

A: Regulatory information indicates that combining this medication with certain nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, may be associated with an increased risk of fluid retention, swelling, or new onset or worsening of high blood pressure.

Q: Can I take Ofuxal if I am also taking a popular herbal supplement like St. John's Wort?

A: Official documents emphasize avoiding certain prescription medicines that are strong CYP3A4 inhibitors. While herbal supplements like St. John's Wort are not explicitly listed, they are known to affect the same CYP3A4 enzyme pathway. Regulatory guidance recommends informing a healthcare professional of all supplements used.

Q: What does the official information say about Ofuxal and driving or operating machinery?

A: Official warnings advise patients to avoid activities that require high mental alertness, such as driving or operating hazardous machinery, until they are certain how the medication affects them. This is due to the potential for dizziness, lightheadedness, or fainting.

Q: What percentage of patients experience improvement in the clinical trials for Ofuxal?

A: Official clinical study reports provide specific measures of efficacy, such as the mean improvement in the International Prostate Symptom Score (IPSS) and increases in Peak Urinary Flow Rate. These numeric scores detail the overall group patterns observed in patients receiving the medicine compared to the placebo groups.

Q: Does taking Ofuxal require any regular blood work or monitoring tests?

A: The official product labeling requires that prostate carcinoma (cancer) must be ruled out before initiating treatment using a standard blood test (Prostate-Specific Antigen or PSA). This is because BPH and cancer can present with similar urinary symptoms.

Q: Does Ofuxal have any known interactions with alcohol?

A: Official patient information states that consuming alcohol while taking this medication may significantly increase the risk of side effects such as dizziness and fainting spells (postural hypotension).

Q: Is Ofuxal considered a 'first-line' treatment option, or is it for later use?

A: Regulatory-based systematic reviews often describe alpha-blockers as a first-choice treatment option for men experiencing moderate-to-severe lower urinary tract symptoms. This classification reflects the drug class's demonstrated superiority over placebo in clinical trials.

Q: Do different age groups experience different types or severity of side effects with Ofuxal?

A: Official prescribing information notes that older adults (geriatric patients) may be more sensitive to the effects of the medicine than younger adults. Caution is advised for this population due to the increased likelihood of age-related liver, kidney, or heart conditions.

Q: What should a patient do if they suspect an interaction between Ofuxal and another product? (Non-directive guidance)

A: Regulatory guidance consistently recommends that patients inform their healthcare professional of all concomitant medications, nonprescription medicines, and herbal supplements they are currently using.

How to Store and Dispose of Ofuxal?

The official storage and disposal requirements for Ofuxal (Alfuzosin Hydrochloride extended-release tablets) are strictly defined by regulatory documents to maintain product integrity and safety.

Storage Conditions

The tablets must be stored at controlled room temperature, specifically maintained between 20 C and 25 C (68 F and 77 F), with permitted brief excursions up to 30 C. It is mandatory to keep the medicine in its original container, which must be kept tightly closed. The product must be protected from moisture and excessive heat, and must not be frozen.

Disposal and Child Safety

All medicines must be stored out of the sight and reach of children. Unused or expired tablets should be disposed of via an authorized drug take-back program. If a program is unavailable, follow the regulatory guidance for disposal in the household trash by mixing the tablets with an undesirable substance and sealing the mixture; the medicine should not be flushed down a toilet or poured down a drain.